Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Tetrabenazine (Xenazine) - Uses, Dose, Side effects

Tetrabenazine (Xenazine) reduces the excitatory neurotransmitters in the brain. It is used for hyperkinetic movement disorders.

Indications of Tetrabenazine (Xenazine):

Chorea associated with Huntington disease:
- It is a prescription medication used to treat chorea brought on by Huntington's disease.
- Treatment of Tourette syndrome and other persistent tic disorders
Off Label Use of Tetrabenazine in Adults:
- Tardive dyskinesia

Tetrabenazine (Xenazine) dose in Adults

Note: Individual needs should guide the gradual titration of the dose.

Tetrabenazine (Xenazine) dose in the treatment of Chorea associated with Huntington disease:

Starting dosage is 12.5 mg per mouth once daily in the morning; after a week, the amount may be increased to 12.5 mg b.i.d.
When the dosage is above 37.5 mg per day, it should be divided into three doses and may be raised by 12.5 mg per day per week.
25 mg is the maximum single dose.
Patients requiring doses >50 mg/day:
- Genotype for CYP2D6:
  - Extensive and intermediate metabolizers:
    - Maximum: 100 mg/day; 37.5 mg/dose
  - Poor metabolizers:
    - Maximum: 50 mg/day; 25 mg/dose
  - Concomitant use with strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine, quinidine):
    - Maximum: 50 mg/day; 25 mg/dose.

Note:

If treatment is stopped for more than five days, re-titration is required.
If your treatment is stopped for more than five days, you should resume your maintenance dose.

Tetrabenazine (Xenazine) dose in the treatment of Tardive dyskinesia:

Note: Individual doses are determined by tolerance and efficacy.

Starting dosage is 50 mg per day, divided into two doses. If necessary, the amount may be increased daily by 50 mg every 14 days, up to a maximum of 150 mg per day, divided into two doses.
As an alternative, a starting dose of 25 to 37.5 mg/day per oral in 2 or 3 split doses has been suggested, with weekly increases or decreases in dose indicated in increments of 12.5 mg/day.
The usual maximum tolerated dose:
- 75 mg per day in three separate doses; in extremely unusual circumstances, dosages as high as 200 mg per day have been utilised.

Tetrabenazine (Xenazine) dose in the treatment of Tourette syndrome:

Starting dose: 12.5 mg twice or three times daily; dose may be raised by 12.5 mg daily at intervals of one week; dose should be increased to the highest tolerable and effective level.
The usual maximum tolerated dosage:
- 25 mg 3 times daily.
The maximum recommended dose:
- 200 mg/day.

Tetrabenazine (Xenazine) dose in Children

Tetrabenazine (Xenazine) dose in the treatment of Tourette syndrome:

Children and Adolescents:
- 50% of the adult dose should be given.
- Starting dose: 6.25 mg twice or three times per day by mouth; dose may be increased by 6.25 mg per day at weekly intervals; dose should be titrated gradually to maximum acceptable and effective dose.
Dosing adjustment for toxicity:
- Children and Adolescents:
  - For toxicities/adverse responses such akathisia, restlessness, parkinsonism, sleeplessness, depression, suicidality, anxiety, and sedation, upward dose titration and dose reduction must be suspended.
  - In the event of negative reactions, therapy should be discontinued. (No tapering is required.

Pregnancy Risk Category: C

Studies on animal reproduction revealed negative outcomes.
There is limited information available on the use of tetrabenazine during pregnancy.

Use of Tetrabenazine while breastfeeding

Breast milk does not contain any Tetrabenazine.
According to the manufacturer's instructions, the risk/benefits of breastfeeding to an infant and the benefits to the mother will determine whether or not to continue breastfeeding during therapy.

Tetrabenazine (Xenazine) dose in Renal Disease:

There are no dosage adjustments provided in the manufacturer's labeling.

Tetrabenazine (Xenazine) dose in Liver Disease:

Use is contraindicated in case of hepatic impairment.

Side effects of Tetrabenazine (Xenazine):

Note:

Usually dose-related, adverse effects may disappear with lower doses. adverse consequences for adults with chorea linked to Huntington's disease have been observed.

Common Side Effects of Tetrabenazine (Xenazine):

Central Nervous System:
- Drowsiness
- Sedation
- Depression
- Extrapyramidal Reaction
- Fatigue
- Insomnia
- Akathisia
- Anxiety
- Falling
Gastrointestinal:
- Nausea
Respiratory:
- Upper Respiratory Tract Infection

Less Common Side Effects of Tetrabenazine (Xenazine):

Central Nervous System:
- Drug-Induced Parkinson's Disease
- Equilibrium Disturbance
- Irritability
- Abnormal gait
- Dizziness
- Dysarthria
- Headache
- Obsessive Rumination
Gastrointestinal:
- Dysphagia
- Vomiting
- Decreased Appetite
- Diarrhea
Genitourinary:
- Dysuria
Hematologic & Oncologic:
- Bruise
Neuromuscular & Skeletal:
- Bradykinesia
Respiratory:
- Bronchitis
- Dyspnea
Miscellaneous:
- Laceration

Contraindications to Tetrabenazine (Xenazine):

Hepatic impairment
Suicidal ideation and severe untreated depression are common.
Combination therapy with deutetrabenazine, valbenazine
Concurrent MAOI therapy or within 2 weeks after MAOI discontinuation
Combination therapy with or start therapy within less than 20 days of stopping reserpine
Hypersensitivity to tetrabenazine and any component of the formulation
If the patient is not under the care and supervision of a psychiatrist familiar with their disorder and the pharmacology of tetrabenazine, he or she should have a history of depression.

Warnings and precautions

Akathisia
- Tetrabenazine can cause akathisia.
- Therefore, it is important to monitor for signs and symptoms such as restlessness or agitation and manage them with withdrawal therapy or dosage reduction.
Depression in the CNS:
- It can lead to CNS depression, which may result in impaired mental or physical abilities.
- It is important to warn patients about driving or operating machinery.
Depression/suicidal thoughts: [US Boxed Warn]
- Huntington disease patients are at high risk of depression and suicidal thoughts. Therefore, it is important to monitor closely throughout treatment.
- Any new or worsening symptoms should be reported to the doctor.
- It should not be given to patients who have had a history of depression, or attempted suicide.
- Tetrabenazine should not be used in patients suffering from severe depression or untreated suicidal thoughts.
- Unresolved depression or suicidal thoughts should prompt the termination of therapy.
The risk of aspiration and esophageal dysmotility:
- Tetrabenazine can cause dysmotility, dysphagia and aspiration. Patients at high risk for aspiration pneumonia should not be given it.
Neuroleptic malignant Syndrome (NMS).
- A neuroleptic malignant syndrome can present with fever, rigidity of the muscles, or instability.
- It is important to monitor your surroundings carefully.
- With the onset NMS, it is important to stop all therapy.
- The recurrence or recurrence may occur if the therapy is restarted.
Ophthalmic effects
- Long-term therapy can cause toxicity and other ophthalmic side effects. In animal studies, it has been shown to bind with melanin-containing tissues.
Orthostatic hypotension
- Orthostatic hypotension is a serious condition that can be caused by BP.
Parkinsonism
- If you experience any symptoms of parkinsonism such as hypertonia, rigidity or bradykinesia (or other signs), withdrawal may be necessary.
Extension of QT
- Different studies have shown that QT interval prolongation can be achieved with either a single drug or in combination.
- Individuals who have a history of cardiac arrhythmias, congenital QT prolongation, or who are taking medicines that prolong QT simultaneously are more vulnerable.
Tardive dyskinesia
- Therapy should be stopped if tardive dyskinesia symptoms develop.
Prolactin-dependent tumors
- Hyperprolactinemia can be caused by Tetrabenazine
- Patients with breast cancer or other prolactin-related tumors should be cautious about using tetrabenazine. Withdrawal may be necessary in certain cases.

Tetrabenazine: Drug Interaction

Risk Factor C (Monitor therapy)
Ajmaline	May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).
Alcohol (Ethyl)	CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).
Alizapride	May enhance the CNS depressant effect of CNS Depressants.
Antipsychotic Agents	Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CloBAZam	May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Cobicistat	May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).
CYP2D6 Inhibitors (Moderate)	May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).
Darunavir	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors).
Dimethindene (Topical)	CNS depressants may have an enhanced CNS depressant impact.
Doxylamine	CNS depressants may have an enhanced CNS depressant impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants.
Dronabinol	CNS depressants may have an enhanced CNS depressant impact.
Esketamine	CNS depressants may have an enhanced CNS depressant impact.
Haloperidol	The QTcprolonging action of haloperidol may be enhanced by QT-prolonging agents (Indeterminate Risk - Avoid).
HydrOXYzine	CNS depressants may have an enhanced CNS depressant impact.
Imatinib	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors).
Kava Kava	CNS depressants' harmful or toxic effects could be increased.
Lofexidine	CNS depressants may have an enhanced CNS depressant impact. Management: Separate drug interaction monographs go into further detail about the medications indicated as exceptions to this book.
Lumefantrine	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors).
Magnesium Sulfate	CNS depressants may have an enhanced CNS depressant impact.
MetyroSINE	Tetrabenazine's negative or hazardous effects could be exacerbated.
Minocycline	CNS depressants may have an enhanced CNS depressant impact.
Mirtazapine	The CNS depressing action of mirtazapine may be enhanced by CNS depressants.
Nabilone	CNS depressants may have an enhanced CNS depressant impact.
Panobinostat	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors).
Peginterferon Alfa-2b	May lower the serum level of CYP2D6 substrates (High risk with Inhibitors). The concentration of CYP2D6 Substrates in the serum may rise when using Peginterferon Alfa-2b (High risk with Inhibitors).
Perhexiline	The serum levels of perhexiline may increase when exposed to CYP2D6 Substrates (High Risk with Inhibitors). The serum concentration of CYP2D6 Substrates may rise in response to perhexiline (High risk with Inhibitors).
Pramipexole	The sedative effects of pramipexole might be enhanced by CNS depressants.
QT-prolonging Agents (Highest Risk)	QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.
QuiNINE	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors).
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Risk Factor D (Consider therapy modification)
Abiraterone Acetate	May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.
Asunaprevir	May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
CYP2D6 Inhibitors (Strong)	Tetrabenazine serum levels can rise. The active alpha- and beta-dihydrotetrabenazine metabolites' concentrations may rise specifically. Treatment: When beginning a potent CYP2D6 inhibitor, the adult dose of tetrabenzine should be cut in half. The maximum daily dose of tetrabenazine for adults is 50 mg when combined with a potent CYP2D6 inhibitor.
Dacomitinib	May elevate CYP2D6 Substrates' serum concentration (High risk with Inhibitors). Management: Steer clear of using dacomitinib at the same time as CYP2D6 subtrates with a limited therapeutic index.
Droperidol	May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromopride	May enhance the adverse/toxic effect of Tetrabenazine.
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Deutetrabenazine	May enhance the adverse/toxic effect of Tetrabenazine.
Metoclopramide	May enhance the adverse/toxic effect of Tetrabenazine.
Monoamine Oxidase Inhibitors	Tetrabenazine may make monoamine oxidase inhibitors more harmful or toxic.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Piribedil	May diminish the therapeutic effect of Tetrabenazine. Tetrabenazine may diminish the therapeutic effect of Piribedil.
Reserpine	May enhance the adverse/toxic effect of Tetrabenazine.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.
Valbenazine	Tetrabenazine may intensify Valbenazine's harmful or toxic effects.

Monitoring parameters:

Orthostatic blood pressure
Therapy with psychiatric status
Neuroleptic malignant Syndrome: Signs and Symptoms
Suicide ideation and signs/symptoms
CYP2D6 genotyping to evaluate metabolizer status (for patients requiring more than 50 mg/day).
Movement disorder improvement

How to administer Tetrabenazine (Xenazine)?

It should be given orally without regard to food.

Mechanism of action of Tetrabenazine (Xenazine):

A reversible inhibitor of the human vesicular monoaminetransporter type 2 is tetrabenazine (VMAT-2).
Depletion of monoamine storage results from a reduction in monoamine uptake into synaptic arteries.
Hydroxytetrabenazine, also known as HTBZ, inhibits VMAT-2 and has a weak binding affinity to dopamine D receptors.

Time: 16-24 hours (at steady state); chorea can recur in 12-18 hours.

ProteinBinding: 82% to 85 %; Metabolites 59% to 68%

Metabolism: The liver produces a large amount of active metabolites rapidly and extensively: Alpha and Beta hydroxy-tetrabenazine via CYP2D6.

Bioavailability: Low and erratic due to large first-pass effects. Food is not likely to affect this condition.

Eliminating half-life:

Alpha-HTBZ: 7 Hours, 10 Hours (hepatic impairment).
Beta-HTBZ: 5 hours or 8 hours (hepatic impairment).
Tetrabenazine: 17.5 Hours (hepatic impairment).

Time until plasma concentration peaks: Metabolites: In 1 to 1.5 Hours

Excretion:

Urine (75% for metabolites, 10% for alpha and beta HTBZ).
Feces (7%-16%)

International Brands of Tetrabenazine:

APO-Tetrabenazine
Nitoman
PMS-Tetrabenazine
Choreazine
Dystardis
Feinardon
Motetis
Nitoman
Revocon
Tetmodis
Tetrazin
Trenazin
Xenazina
Xenazine

Tetrabenazine Brand Names in Pakistan:

No Brands Available in Pakistan.

Disclaimer Notice:

Emedz.net is not an online pharmacy:

We are not affiliated with any pharmaceutical companies:

Tetrabenazine (Xenazine) - Uses, Dose, Side effects

Indications of Tetrabenazine (Xenazine):

Chorea associated with Huntington disease:

Off Label Use of Tetrabenazine in Adults:

Tetrabenazine (Xenazine) dose in Adults

Tetrabenazine (Xenazine) dose in the treatment of Chorea associated with Huntington disease:

Patients requiring doses >50 mg/day:

Genotype for CYP2D6:

Note:

Tetrabenazine (Xenazine) dose in the treatment of Tardive dyskinesia:

Tetrabenazine (Xenazine) dose in the treatment of Tourette syndrome:

Tetrabenazine (Xenazine) dose in Children

Tetrabenazine (Xenazine) dose in the treatment of Tourette syndrome:

Children and Adolescents:

Dosing adjustment for toxicity:

Pregnancy Risk Category: C

Tetrabenazine (Xenazine) dose in Renal Disease:

Tetrabenazine (Xenazine) dose in Liver Disease:

Side effects of Tetrabenazine (Xenazine):

Note:

Common Side Effects of Tetrabenazine (Xenazine):

Central Nervous System:

Gastrointestinal:

Respiratory:

Less Common Side Effects of Tetrabenazine (Xenazine):

Central Nervous System:

Gastrointestinal:

Genitourinary:

Hematologic & Oncologic:

Neuromuscular & Skeletal:

Respiratory:

Miscellaneous:

Contraindications to Tetrabenazine (Xenazine):

Warnings and precautions

Akathisia

Depression in the CNS:

Depression/suicidal thoughts: [US Boxed Warn]

The risk of aspiration and esophageal dysmotility:

Neuroleptic malignant Syndrome (NMS).

Ophthalmic effects

Orthostatic hypotension

Parkinsonism

Extension of QT

Tardive dyskinesia

Prolactin-dependent tumors

Monitoring parameters:

How to administer Tetrabenazine (Xenazine)?

Mechanism of action of Tetrabenazine (Xenazine):

International Brands of Tetrabenazine:

Tetrabenazine Brand Names in Pakistan:

Recent Posts

Related Posts